Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.61
-$0.08(-1.45%)
At close: 4:00 PM EDT
$5.61
-$0.08(-1.45%)
Day’s Range― - ―
52-Week Range$3.86 - $7.01
Previous Close$5.57
Volume3.79M
Average Volume (3M)2.36M
Market Cap
$867.04M
Enterprise Value$1.42B
Total Cash (Recent Filing)$173.03M
Total Debt (Recent Filing)$30.11M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding205,460,020
10 Day Avg. Volume2,385,637
30 Day Avg. Volume2,361,519
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.57
Enterprise Value/Ebitda-10.21
Forecast
1Y Price Target
$11.33Price Target Upside102.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$2.69M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityA relatively low debt burden and positive equity provide Savara with a balance-sheet cushion compared with more highly leveraged early-stage companies. This can preserve financial flexibility and reduce the immediate pressure of debt servicing while development programs advance.
Focused Rare-Disease PipelineConcentration on rare respiratory diseases gives Savara a defined strategic identity and keeps research resources directed toward a specific unmet medical area. The lead program provides a clear development focus, although the company remains dependent on clinical progress.
Financing FlexibilityExpanded share authorization and incentive capacity can give Savara additional tools to fund research, retain employees, and support corporate development. This flexibility is relevant for a clinical-stage company whose operations currently require substantial external financing.
Bears Say
No Commercial RevenueThe absence of revenue means Savara has not yet established a commercial product base or internally generated funding stream. Until a therapy reaches the market, the company remains reliant on capital access to sustain operations and advance its clinical pipeline.
Widening Net LossesProgressively larger losses indicate that operating expenses are expanding faster than any offsetting income, increasing the resources required to sustain development. Continued deterioration can reduce financial flexibility and raise the amount of capital needed before potential commercialization.
Heavy Cash Burn And Funding DependencePersistent, high cash burn prevents Savara from self-funding its operations and makes continued access to external financing strategically important. This creates ongoing funding exposure over the next several quarters, particularly while revenue remains absent.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $3.86 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $867.04M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Aug 11, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.018.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.16.
How many shares outstanding does Savara have?
Savara has 205,460,020 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 2.334%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (102.02% Upside)
$11.33 (102.02% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 49.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.5%
Last 30 Days ▲ 27.2%
Last 30 Days ▲ 27.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.42%
12-Months-Change
Fundamentals
Return on Equity
-90.28%
Trailing 12-Months
Asset Growth
17.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.33
▲(102.02% Upside)
Technical Analysis
Ownership Overview
3.11% Insiders
7.46% Mutual Funds
0.14% Other Institutional Investors
77.75% Public Companies and
Individual Investors